Targets › CAMK2D
1 program from 1 company in 2 trials: 2 Phase 2; Cardiovascular; next expected readout Apr 2027.
Calcium/calmodulin-dependent protein kinase involved in the regulation of Ca(2+) homeostatis and excitation-contraction coupling (ECC) in heart by targeting ion channels, transporters and accessory proteins involved in Ca(2+) influx into the myocyte, Ca(2+) release from the sarcoplasmic reticulum (SR), SR Ca(2+) uptake and Na(+) and K(+) channel transport. Targets also transcription factors and signaling molecules…. (UniProt, Q13557)
Open in Phaseline: the race on CAMK2D, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Cardurion Pharmaceuticals | CRD-4730 Calcium/calmodulin-dependent protein kinase II (CaMKII) inhibitor | CAMK2A, CAMK2B, CAMK2D, CAMK2G | Phase 2 | Catecholaminergic Polymorphic Ventricular Tachycardia; Heart Failure With Reduced Ejection Fraction (HFrEF) | Apr 2027 |
Catecholaminergic Polymorphic Ventricular Tachycardia (1) Heart Failure With Reduced Ejection Fraction (HFrEF) (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.